Application No.: 09/622,253

Page 2

## **Listing of Claims:**

1. (currently amended) A method of producing a derivatised antibody, which derivitised antibody is capable of binding to an immobilised IgG, the method comprising:

treating a precursor antibody to expose a carbohydrate chain of the precursor antibody from an interstitial site on thea surface of the precursor antibody; and,

chemically derivatising <u>one or more amino acid residues of</u> the precursor antibody to prevent the carbohydrate from returning to the interstitial site so that <u>thea</u> resulting derivatised antibody is capable of binding to the immobilised IgG.

- 2. (original) The method of claim 1, wherein the precursor antibody has Fc associated carbohydrate chains which terminate with an N-acetylglucosamine residue.
- 3. (previously presented) The method of claim 1, comprising treating the precursor antibody with  $\beta$ -galactosidase to remove terminal galactose residues.
- **4.** (previously presented) The method of claim 1, wherein the chemical derivatising comprises thiolating the antibody in the presence of carbonate.
- **5.** (previously presented) The method of claim 1, comprising separating derivatised antibodies which <u>stackean associate with one another</u> at a site of the immobilised IgG, from those derivatised antibodies which <u>do ean</u>not so <u>stackassociate</u>.
- **6.** (previously presented) The method of claim 5, wherein separating the derivatised antibodies is performed by Con A chromatography or by pH elution from a Protein A affinity column.
- 7. (withdrawn) A derivatised antibody made by the method of claim 1, wherein the derivatised antibody is derivatised to expose a carbohydrate chain thereof, so that the derivatised antibody is capable of binding to the immobilised IgG.
- 8. (withdrawn) The derivatised antibody of claim 7, wherein the carbohydrate chain is an Fc carbohydrate chain.
- 9. (withdrawn) The derivatised antibody of claim 7, wherein the carbohydrate chain terminates with an N-acetylglucosamine residue.

Application No.: 09/622,253

Page 3

- 10. (withdrawn) The derivatised antibody of claim 7, wherein the carbohydrate chains of the derivatised antibody are capable of specifically binding to a binding site on the derivatised antibody, when said derivatised antibody is immobilised.
- 11. (withdrawn) The derivatised antibody of claim 7, wherein the immobilised IgG is a galactosyl IgG.
- 12. (withdrawn) The derivatised antibody of claim 7, wherein the derivatised antibody is conjugated to a label, toxin, drug, prodrug or effector.
- 13. (withdrawn) The derivatised antibody of claim 7, wherein the derivatised antibody is specific for an inflammatory mediator.
- 14. (withdrawn) The derivatised antibody of claim 7, wherein the derivatised antibody is formulated for medical treatment or for diagnosis of a condition associated with the immobilised IgG.
- 15. (withdrawn) The derivatised antibody of claim 14, wherein the derivatised antibody provides for the diagnosis or treatment of an autoimmune disorder.
- 16. (withdrawn) The derivatised antibody of claim 15, wherein the autoimmune disorder is selected from the group consisting of: rheumatoid arthritis, juvenile arthritis, Crohn's disease, type I insulin dependent diabetes, type II diabetes, sarcoidosis, erythema nodosum leprosum, and tuberculosis.
- 17. (withdrawn) The antibody of claim 16, wherein the antibody is formulated for diagnosis or treatment of erosive joint disease and the immobilised IgG is anti-type II collagen IgG.
- 18. (withdrawn) A medicament comprising the derivatised antibody of Claim 7, which medicament treats or diagnoses a condition associated with immobilized IgG.
- 19. (withdrawn) The medicament of claim 18, wherein the condition associated with immobilised IgG is an autoimmune disorder.
- 20. (withdrawn) The medicament of claim 19, wherein the autoimmune disorder is selected from rheumatoid arthritis, juvenile arthritis, Crohn's disease, type I insulin dependent diabetes, type II diabetes, sarcoidosis, erythema nodosum leprosum and tuberculosis.
- 21. (withdrawn) The medicament of claim 18, wherein the condition is erosive joint disease and the immobilised IgG is anti-type II collagen IgG.

Application No.: 09/622,253

Page 4

22. (withdrawn) A method for the in vivo diagnosis of a condition associated with immobilised IgG, the method comprising:

- a. exposing a Patient to the derivatised antibody of claim 7, which derivatised antibody has been labeled; and,
  - b. detecting the label, thereby detecting the presence of the immobilised IgG.
- 23. (withdrawn) A pharmaceutical composition comprising a derivatised antibody made by the method of claim 1, and a carrier.

Application No.: 09/622,253

Page 5

QUINE INTELLECTUAL PROPERTY LAW GROUP

P.O. BOX 458, Alameda, CA 94501

Tel: 510 769-3510 Fax: 510 337-7877

PTO Customer No.: 22798
Deposit Account No.: 50-0893

Respectfully submitted,

Jonathan Alan Quine Reg. No: 41,261

## Attachments:

1) A transmittal sheet;

2) A receipt indication postcard.